Literature DB >> 365185

Tgamma cells in systemic lupus erythematosus. Variation with disease activity.

M E Hamilton, J B Winfield.   

Abstract

Circulating T cells bearing receptors for the Fc portion of IgG (T gamma) were identified by sensitive immunofluorescent techniques with rabbit IgG b4 allotype/anti-b4 complexes. A twofold decrease in both proportion and absolute number of T gamma cells was found in patients with active systemic lupus erythematosus (SLE) relative to values obtained during disease remission. The reduction in T gamma cells was most evident in patients with severe hypocomplementemia. A deficit of T gamma cells in active patients was not demonstrated. The percentage of total T cells rosetting with sheep erythrocytes was reduced in peripheral blood of most patients regardless of disease activity status, but particularly during SLE exacerbation. Cells lacking intrinsic surface immunoglobulin, IgG Fc receptors, and receptors for sheep erythrocytes were increased. These cells, operationally termed null, exhibited an inverse linear relationship with T cells that was not apparent in regression analyses performed against other lymphocyte subpopulations. Such differences were not found for B cells and IgG receptor-bearing non-B/non-T cells which were present in normal proportions in virtually all patients. The origin and functional significance of these unusual lymphocyte subpopulation abnormalities are discussed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 365185     DOI: 10.1002/art.1780220101

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

1.  Detection of antilymphocyte antibody with two-color method in systemic lupus erythematosus and its heterogeneous specificities against human T-cell subsets.

Authors:  K Okudaira; H Nakai; T Hayakawa; T Kashiwado; K Tanimoto; Y Horiuchi; T Juji
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

2.  Monoclonal antibody investigation in rheumatoid arthritis: presence of a T cell subpopulation bearing a double marker.

Authors:  G Lapadula; M Covelli; R Numo; G Tricarico; G Amendoni; C Berlingerio
Journal:  Clin Rheumatol       Date:  1984-06       Impact factor: 2.980

3.  Immunoregulatory T cells in the peripheral blood of patients with Bechterew's syndrome.

Authors:  O Vinje; J H Dobloug; O Førre; P Møller; O J Mellbye
Journal:  Ann Rheum Dis       Date:  1982-02       Impact factor: 19.103

4.  Subpopulations of T lymphocytes in patients with ankylosing spondylitis.

Authors:  E Nilsson; G Biberfeld
Journal:  Ann Rheum Dis       Date:  1980-12       Impact factor: 19.103

5.  Natural killer cell in systemic lupus erythematosus. Defects in effector lytic activity and response to interferon and interferon inducers.

Authors:  W L Sibbitt; P M Mathews; A D Bankhurst
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

6.  Natural cytotoxicity in systemic lupus erythematosus: mechanisms of suppression by inhibitory serum factors.

Authors:  W L Sibbitt; C J Froelich; A D Bankhurst
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

7.  Differences in the production of and/or the response to interleukin-2 by T lymphocytes from patients with the various connective tissue diseases.

Authors:  J Alcocer-Varela; A Laffón; D Alarcón-Segovia
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

8.  Impaired antigen-specific suppressor cell activity in patients with systemic lupus erythematosus.

Authors:  D Gladman; E Keystone; M Urowitz; D Cane; L Poplonski
Journal:  Clin Exp Immunol       Date:  1980-04       Impact factor: 4.330

9.  Studies on human blood lymphocytes with iC3b (type 3) complement receptors: III. Abnormalities in patients with active systemic lupus erythematosus.

Authors:  J D Gray; A Lash; A C Bakke; R C Kitridou; D A Horwitz
Journal:  Clin Exp Immunol       Date:  1987-03       Impact factor: 4.330

10.  Cytotoxic responses to alloantigens in systemic lupus erythematosus.

Authors:  G C Tsokos; J E Balow
Journal:  J Clin Immunol       Date:  1981-10       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.